Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
Business Wire•18/11/2026•08:00 ET
0
Key Highlights
- ➤$7.6 million cash, with substantial doubt about funding operations for next 12 months
- ➤Approximately $4.0 million registered direct offering closed September 30, 2026
- ➤David Margrave appointed interim CEO after Panna Sharma resigned November 15
- ➤LP-184 TNBC trial’s first site engaged to begin patient enrollment
- ➤Q3 operating loss $5.4 million, including $2.0 million proposed settlement accrual
Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
First clinical site engaged for Phase 1b/2 trial in triple negative breast cancer; Taiwan Approvals Open Part 2 of Phase 2 HARMONIC™ Trial of LP-300 in L858R Never-Smoker NSCLC; Peer-Reviewed Publication of LP-184 Phase 1a Glioblastoma Data Supports Planned Phase 1b/2a Combination Trial with Spironolactone; Approximately $4.0 Million Registered Direct Offering Closed September 30, 2026; Leadership Transition with CFO David Margrave Appointed Interim Chief Executive Officer
Get started
Create a free account to read the full story.
